The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 48 | — | 20.1x | Near average | |
Growth | 80 | 256.8% | 5.6% | Above average | |
Quality | 40 | -41.4% | 7.6% | Near average | |
Safety | 59 | -0.4x | 0.4x | Near average | |
Capital Return | 28 | — | 2.19% | Below average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Madrigal Pharmaceuticals, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Madrigal Pharmaceuticals, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
Madrigal stock shows complete stability in the average price target at 731.25 dollars over the past 30 days, with a consensus from 5 analysts. Despite the steady price forecasts, there is a notable dispersion between the low of 571 dollars and the highly optimistic high of 964 dollars, reflecting a variance in estimating the market penetration speed for fatty liver treatments.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.